Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$27.65 USD

27.65
18,763,599

-0.05 (-0.18%)

Updated May 3, 2024 03:01 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (194 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

    Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

    Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

      J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

      Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

        The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental

        The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental

          Stock Market News for November 21, 2016

          Rising rate hike possibilities boosted the dollar to its best settlement in 13 years, which in turn dragged the benchmarks into the red on Friday.

            Stock Market News for November 08, 2016

            Benchmarks ended higher on Monday after the FBI said that it would not press criminal charges against Democratic nominee Hillary Clinton

              The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

              The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

                Mark Vickery headshot

                Fed Meets, Q3 Earnings Continue, Election Uncertainty Rules

                With the omnipresent General Election looming, little else matters to investors at this point.

                  Stock Market News for October 19, 2016

                  Upbeat earnings results led the benchmarks to close in the green on Tuesday

                    Mark Vickery headshot

                    Market News Over Summer Vacation: PFE, AZN, TSLA, LZB

                    You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.

                      Mark Vickery headshot

                      M&A Boosts Intersil, Syngenta and Medivation in Pre-Market

                      We???re seeing big gains among smaller companies ready to be purchased by much bigger fish: PFE, MDVN, SYT, ISIL.

                        Sheraz Mian headshot

                        New Research Reports for Pfizer, Cisco & Visa

                        Today's must-read reports are for Pfizer (PFE), Cisco (CSCO) and Visa (V).

                          Mark Vickery headshot

                          Q2 Earnings Reports Come in Mixed, Futures Down Slightly

                          Q2 earnings season may have passed the midway point last week, but plenty of important companies are reporting earnings this morning: PFE, PG, MNT, CVS, SODA and RCL.

                            John Blank headshot

                            Don't Make It Complicated, Own Drug Stocks

                            The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.

                              Neena Mishra headshot

                              Bull of the Day: Pfizer (PFE)

                              Bet on this big pharma stock for growth, stability and income.

                                Kevin Cook headshot

                                Bear of the Day: AbbVie (ABBV)

                                Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus

                                  Stock Market News for May 04, 2016

                                    Stock Market News for April 07, 2016

                                    Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks

                                      Stock Market News for March 22, 2012

                                      Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.

                                        Tracey Ryniec headshot

                                        This Week's Top Value Stocks: (PFE) (MYL)

                                        Looking for the best value stocks? Tracey Ryniec, Stock Strategist at Zacks Investment Research, discusses two stocks that might be worth a closer look by value investors: Pfizer (PFE) and Mylan NV (MYL).

                                          Arpita Dutt headshot

                                          Pharma Industry Outlook: Pricing Pressure and M&As in Focus

                                          According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.

                                            Arpita Dutt headshot

                                            Pharma Industry Outlook: Pricing Pressure and M&As in Focus

                                            According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.

                                              Sheraz Mian headshot

                                              Q1 Earnings Scorecard - S&P 500 vs. Russell 2000

                                              The picture emerging from the Q1 earning season is one of widespread weakness.